article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

billion in 2028, according to a report by Arizton. percent up to 2028. percent between the forecast period: 2023 and 2028. percent between the forecast period 2023-2028. Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 Having been valued at $27.04 percent in 2022.

article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. New technologies are being developed that allow for virtual clinical trials and other cost-lowering development costs. But even though the government may be saving money, ordinary taxpayers probably won’t see any discounts. healthcare.

article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 million, the company disclosed in a proxy filing” No biosimilar will take on Humira’s $16 billion in 2020 U.S.

Pharma 186
article thumbnail

Lilly, LA28 Olympic and Paralympic Games Announce Collaboration Through 2028

PharmExec

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 110
article thumbnail

Elite Teledentistry Companies in the USA

Medico Reach

million by 2028 , with more teledentistry companies entering the market. 24/7 service and free dental consultation Personalized video consultation and prescriptions at $49 The platform accepts dental insurance Patience can attach dental x-rays for a better consultation. That’s why the teledentistry industry is gradually evolving.